SERA PROGNOSTICS INC-A (SERA) Fundamental Analysis & Valuation

NASDAQ:SERA • US81749D1072

1.91 USD
-0.09 (-4.5%)
Last: Mar 6, 2026, 01:57 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This SERA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

3

Overall SERA gets a fundamental rating of 3 out of 10. We evaluated SERA against 520 industry peers in the Biotechnology industry. While SERA seems to be doing ok healthwise, there are quite some concerns on its profitability. SERA is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. SERA Profitability Analysis

1.1 Basic Checks

  • In the past year SERA has reported negative net income.
  • SERA had a negative operating cash flow in the past year.
  • In the past 5 years SERA always reported negative net income.
  • SERA had a negative operating cash flow in each of the past 5 years.
SERA Yearly Net Income VS EBIT VS OCF VS FCFSERA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M

1.2 Ratios

  • SERA's Return On Assets of -30.17% is fine compared to the rest of the industry. SERA outperforms 65.96% of its industry peers.
  • The Return On Equity of SERA (-39.70%) is better than 70.19% of its industry peers.
Industry RankSector Rank
ROA -30.17%
ROE -39.7%
ROIC N/A
ROA(3y)-40.43%
ROA(5y)-55.85%
ROE(3y)-55.05%
ROE(5y)-196.88%
ROIC(3y)N/A
ROIC(5y)N/A
SERA Yearly ROA, ROE, ROICSERA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -200 -400 -600

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for SERA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SERA Yearly Profit, Operating, Gross MarginsSERA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 -20K -40K -60K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. SERA Health Analysis

2.1 Basic Checks

  • SERA does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • SERA has more shares outstanding than it did 1 year ago.
  • SERA has more shares outstanding than it did 5 years ago.
  • The debt/assets ratio for SERA has been reduced compared to a year ago.
SERA Yearly Shares OutstandingSERA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M
SERA Yearly Total Debt VS Total AssetsSERA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M

2.2 Solvency

  • SERA has an Altman-Z score of -3.04. This is a bad value and indicates that SERA is not financially healthy and even has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -3.04, SERA is in line with its industry, outperforming 45.77% of the companies in the same industry.
  • SERA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -3.04
ROIC/WACCN/A
WACC8.71%
SERA Yearly LT Debt VS Equity VS FCFSERA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

  • SERA has a Current Ratio of 1.89. This is a normal value and indicates that SERA is financially healthy and should not expect problems in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 1.89, SERA is doing worse than 77.31% of the companies in the same industry.
  • SERA has a Quick Ratio of 1.89. This is a normal value and indicates that SERA is financially healthy and should not expect problems in meeting its short term obligations.
  • SERA has a Quick ratio of 1.89. This is in the lower half of the industry: SERA underperforms 75.96% of its industry peers.
Industry RankSector Rank
Current Ratio 1.89
Quick Ratio 1.89
SERA Yearly Current Assets VS Current LiabilitesSERA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. SERA Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 22.22% over the past year.
  • SERA shows a small growth in Revenue. In the last year, the Revenue has grown by 1.06%.
  • The Revenue has been growing by 14.00% on average over the past years. This is quite good.
EPS 1Y (TTM)22.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
Revenue 1Y (TTM)1.06%
Revenue growth 3Y-1.27%
Revenue growth 5Y14%
Sales Q2Q%-44.83%

3.2 Future

  • The Earnings Per Share is expected to grow by 9.55% on average over the next years. This is quite good.
  • The Revenue is expected to grow by 186.41% on average over the next years. This is a very strong growth
EPS Next Y27.88%
EPS Next 2Y13.08%
EPS Next 3Y12.07%
EPS Next 5Y9.55%
Revenue Next Year-13.64%
Revenue Next 2Y165.43%
Revenue Next 3Y190.62%
Revenue Next 5Y186.41%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
SERA Yearly Revenue VS EstimatesSERA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 10M 20M 30M
SERA Yearly EPS VS EstimatesSERA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 -0.5 -1 -1.5

More info and screens

Find the best growth stocksShow best growing peers

0

4. SERA Valuation Analysis

4.1 Price/Earnings Ratio

  • SERA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SERA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SERA Price Earnings VS Forward Price EarningsSERA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SERA Per share dataSERA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 1.5 2

4.3 Compensation for Growth

  • SERA's earnings are expected to grow with 12.07% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y13.08%
EPS Next 3Y12.07%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. SERA Dividend Analysis

5.1 Amount

  • SERA does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

SERA Fundamentals: All Metrics, Ratios and Statistics

SERA PROGNOSTICS INC-A

NASDAQ:SERA (3/6/2026, 1:57:43 PM)

1.91

-0.09 (-4.5%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13
Earnings (Next)03-25
Inst Owners59.18%
Inst Owner Change-3.01%
Ins Owners2.56%
Ins Owner Change-2.32%
Market Cap73.71M
Revenue(TTM)95.00K
Net Income(TTM)-32.63M
Analysts86.67
Price Target5.1 (167.02%)
Short Float %0.86%
Short Ratio6.34
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)25.93%
Min EPS beat(2)21.57%
Max EPS beat(2)30.28%
EPS beat(4)3
Avg EPS beat(4)16.12%
Min EPS beat(4)-2.12%
Max EPS beat(4)30.28%
EPS beat(8)6
Avg EPS beat(8)10%
EPS beat(12)10
Avg EPS beat(12)12.52%
EPS beat(16)12
Avg EPS beat(16)9.87%
Revenue beat(2)0
Avg Revenue beat(2)-77.95%
Min Revenue beat(2)-81.55%
Max Revenue beat(2)-74.36%
Revenue beat(4)1
Avg Revenue beat(4)-38.12%
Min Revenue beat(4)-81.55%
Max Revenue beat(4)56.86%
Revenue beat(8)1
Avg Revenue beat(8)-51.37%
Revenue beat(12)3
Avg Revenue beat(12)-41.61%
Revenue beat(16)3
Avg Revenue beat(16)-38.88%
PT rev (1m)0%
PT rev (3m)81.82%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-2.7%
EPS NY rev (1m)0%
EPS NY rev (3m)7.89%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-50%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-60.42%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 775.86
P/FCF N/A
P/OCF N/A
P/B 0.9
P/tB 0.91
EV/EBITDA N/A
EPS(TTM)-0.77
EYN/A
EPS(NY)-0.71
Fwd EYN/A
FCF(TTM)-0.68
FCFYN/A
OCF(TTM)-0.67
OCFYN/A
SpS0
BVpS2.13
TBVpS2.11
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -30.17%
ROE -39.7%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-40.43%
ROA(5y)-55.85%
ROE(3y)-55.05%
ROE(5y)-196.88%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 50.39%
Cap/Sales 481.05%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.89
Quick Ratio 1.89
Altman-Z -3.04
F-Score3
WACC8.71%
ROIC/WACCN/A
Cap/Depr(3y)83.45%
Cap/Depr(5y)92.8%
Cap/Sales(3y)588.1%
Cap/Sales(5y)777.86%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)22.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
EPS Next Y27.88%
EPS Next 2Y13.08%
EPS Next 3Y12.07%
EPS Next 5Y9.55%
Revenue 1Y (TTM)1.06%
Revenue growth 3Y-1.27%
Revenue growth 5Y14%
Sales Q2Q%-44.83%
Revenue Next Year-13.64%
Revenue Next 2Y165.43%
Revenue Next 3Y190.62%
Revenue Next 5Y186.41%
EBIT growth 1Y-2.53%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-8.62%
EBIT Next 3Y9.29%
EBIT Next 5YN/A
FCF growth 1Y6.22%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y6.86%
OCF growth 3YN/A
OCF growth 5YN/A

SERA PROGNOSTICS INC-A / SERA FAQ

What is the fundamental rating for SERA stock?

ChartMill assigns a fundamental rating of 3 / 10 to SERA.


What is the valuation status of SERA PROGNOSTICS INC-A (SERA) stock?

ChartMill assigns a valuation rating of 0 / 10 to SERA PROGNOSTICS INC-A (SERA). This can be considered as Overvalued.


How profitable is SERA PROGNOSTICS INC-A (SERA) stock?

SERA PROGNOSTICS INC-A (SERA) has a profitability rating of 1 / 10.


Can you provide the financial health for SERA stock?

The financial health rating of SERA PROGNOSTICS INC-A (SERA) is 5 / 10.